Bone healing induced by local delivery of an engineered parathyroid hormone prodrug
Source abstract
Abstract
Regenerative medicine requires innovative therapeutic designs to accommodate high morphogen concentrations in local depots, provide their sustained presence, and enhance cellular invasion and directed differentiation. Here we present an example for inducing local bone regeneration with a matrix-bound engineered active fragment of human parathyroid hormone (PTH(1-34)), linked to a transglutaminase substrate for binding to fibrin as a delivery and cell-invasion matrix with an intervening plasmin-sensitive link (TGplPTH(1-34)). The precursor form displays very little activity and signaling to osteoblasts, whereas the plasmin cleavage product, as it would be induced under the enzymatic influence of cells remodeling the matrix, was highly active. In vivo animal bone-defect experiments showed dose-dependent bone formation using the PTH-fibrin matrix, with evidence of both osteoconductive and osteoinductive bone-healing mechanisms. Results showed that this PTH-derivatized matrix may have potential utility in humans as a replacement for bone grafts or to repair bone defects.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Blood properties and coagulation · Periodontal Regeneration and Treatments · Hemophilia Treatment and Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Biosynthetic bone grafting10.1097/00003086-199910001-00011 ↗
2. Complications of iliac crest bone graft harvesting10.1097/00003086-199608000-00037 ↗
3. Morbidity at bone graft donor sites10.1097/00005131-198909000-00002 ↗
4. Current concepts of molecular aspects of bone healing10.1016/j.injury.2005.07.019 ↗
5. Principles of bone healing10.3171/foc.2001.10.4.2 ↗
6. The future of bone healing10.1016/j.cpm.2005.07.002 ↗
7. Research directions for bone healing10.1016/j.injury.2005.07.036 ↗
8. The effect of a fibrin–fibronectin/beta-tricalcium phosphate/recombinant human bone morphogenetic protein-2 system on bone formation in rat calvarial defects10.1016/j.biomaterials.2006.02.045 ↗
9. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration10.1038/10473 ↗
10. Localized insulin-like growth factor I delivery to enhance new bone formation10.1016/S8756-3282(03)00207-2 ↗
11. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices10.1038/nbt818 ↗
12. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa10.1021/bc9800769 ↗
13. Cross-link in fibrin polymerized by factor 13: epsilon-(gamma-glutamyl)lysine10.1126/science.160.3830.892 ↗
14. Mechanism of action of guinea pig liver transglutaminase. VI. Order of substrate addition10.1016/S0021-9258(18)83426-3 ↗
15. Hybrid fibrin: proof of the intermolecular nature of – crosslinking units10.1016/S0006-291X(71)80163-8 ↗
16. Amino acid sequence of the factor XIIIa acceptor site in bovine plasma fibronectin10.1016/0014-5793(81)80198-6 ↗
17. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin10.1016/0014-5793(83)80645-0 ↗
18. Development of growth factor fusion proteins for cell-triggered drug delivery10.1096/fj.00-0564fje ↗
19. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension10.1038/74473 ↗
20. Incorporation of heparin-binding peptides into fibrin gels enhances neurite extension: an example of designer matrices in tissue engineering10.1096/fasebj.13.15.2214 ↗
21. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell in growth matrices10.1002/bit.20168 ↗
22. Enhancement of bone healing using non-glycosylated rhBMP-2 released from a fibrin matrix in dogs and cats10.1111/j.1748-5827.2005.tb00269.x ↗
23. Treatment of nonunions with nonglycosylated recombinant human bone morphogenetic protein-2 delivered from a fibrin matrix10.1111/j.1532-950x.2004.04018.x ↗
24. Covalently conjugated VEGF–fibrin matrices for endothelialization10.1016/S0168-3659(01)00266-8 ↗
25. Parathyroid hormone – a bone anabolic and catabolic agent10.1016/j.coph.2005.07.004 ↗
26. The roles of parathyroid hormone and calcitonin in bone remodeling: prospects for novel therapeutics10.2174/187153006776056666 ↗
27. Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone10.1172/JCI118121 ↗
28. Mechanisms balancing skeletal matrix synthesis and degradation10.1042/bj20020165 ↗
29. Parathyroid hormone for the treatment of osteoporosis: a systematic review10.1503/cmaj.050929 ↗
30. Osteoporosis-treating parathyroid hormone peptides: What are they? What do they do? How might they do it?
31. Emerging pharmacologic therapies for osteoporosis10.1517/14728214.12.3.493 ↗
32. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes10.1073/pnas.93.12.5753 ↗
33. Core histones are glutaminyl substrates for tissue transglutaminase10.1074/jbc.271.31.18817 ↗
34. Use of the transglutaminase reaction to study the dissociation of histone N-terminal tails from DNA in nucleosome core particles10.1021/bi9626620 ↗
35. In vitro and rapid in situ transglutaminase assays for congenital ichthyoses – a comparative study10.1046/j.1523-1747.1998.00132.x ↗
36. Upregulation of PTH receptor mRNA expression by dexamethasone in UMR-106 osteoblast-like cells10.1111/j.1601-0825.2006.01234.x ↗
37. Parathyroid hormone responses of cyclic AMP-, serum- and phorbol ester-responsive reporter genes in osteoblast-like UMR-106 cells10.1016/S0303-7207(98)00070-7 ↗
38. Parathyroid hormone (PTH) suppresses rat PTH/PTH-related protein receptor gene promoter10.1006/bbrc.2001.5586 ↗
39. An animal model in sheep for biocompatibility testing of biomaterials in cancellous bones10.1186/1471-2474-7-67 ↗
40. Biocompatibility and resorption of a brushite calcium phosphate cement10.1016/j.biomaterials.2004.11.056 ↗
41. In vivo behavior of three different injectable hydraulic calcium phosphate cements10.1016/j.biomaterials.2003.08.073 ↗
42. In vivo behavior of calcium phosphate scaffolds with four different pore sizes10.1016/j.biomaterials.2006.05.051 ↗
43. Parathyroid hormone (PTH) down-regulates PTH/PTH-related protein receptor gene expression in UMR-106 osteoblast-like cells via a 3′,5′-cyclic adenosine monophosphate-dependent, protein kinase A-independent pathway10.1677/joe.0.1780247 ↗
44. Structure–function relationship of parathyroid hormone: activation of phospholipase-C, protein kinase-A and -C in osteosarcoma cells10.1210/endo.130.1.1727705 ↗
45. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol10.1210/endo-16-5-547 ↗
46. Fibrin glue containing fibroblast growth factor type 1 and heparin decreases platelet deposition10.1016/S0002-9610(97)00090-1 ↗
47. Bone healing in the rat and dog with nonglycosylated BMP-2 demonstrating low solubility in fibrin matrices10.1016/S0736-0266(03)00188-8 ↗
48. Enhanced endothelial cell retention on shear-stressed synthetic vascular grafts precoated with RGD-cross-linked fibrin10.1089/ten.2005.11.887 ↗
49. Bone regeneration following injection of mesenchymal stem cells and fibrin glue with a biodegradable scaffold10.1016/S1010-5182(02)00143-9 ↗
50. Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications10.1517/13543784.16.4.441 ↗